Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2012

Open Access 01-02-2012 | Original Article

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women

Authors: M. Osaki, K. Tatsuki, T. Hashikawa, T. Norimatsu, K. Chiba, S. Motokawa, I. Furuichi, Y. Doiguchi, K. Aoyagi, H. Shindo

Published in: Osteoporosis International | Issue 2/2012

Login to get access

Abstract

Summary

A 36-month observational study compared the incidence of unaffected side hip fracture in Japanese female osteoporosis patients with a history of hip fracture between 173 patients receiving risedronate and 356 risedronate-untreated controls. New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients.

Introduction

The purpose of this study was to investigate the preventive effect of risedronate on second hip fracture immediately following a first hip fracture in Japanese female osteoporosis patients with unilateral hip fracture.

Methods

We conducted a prospective matched cohort study in 184 patients treated with risedronate and 445 patients not receiving risedronate after discharge from hospital. Both groups were followed-up for 36 months, and the incidence of unaffected side hip fracture and the frequency of adverse events were assessed.

Results

Efficacy could be investigated in 173 patients from the risedronate group and 356 patients from the control group. Hip fracture was detected in 5 and 32 patients, respectively. Kaplan–Meier estimates of the 36-month fracture incidence were 4.3% in the risedronate group and 13.1% in the control group (P = 0.010, log-rank test). The hazard ratios (95% confidence intervals) obtained by univariate and multivariate analysis were 0.310 (0.121–0.796) and 0.218 (0.074–0.639), respectively, indicating a significantly lower incidence of unaffected side hip fracture in the risedronate group. Adverse events occurred in 38 patients (48 events) from the risedronate group and 94 patients (108 events) from the control group, with serious adverse events in 21 patients (26 events) and 78 patients (88 events), respectively.

Conclusions

No significant differences were observed between the two groups. The incidence of unaffected side hip fracture was significantly lower in the risedronate group. Accordingly, risedronate may have a preventive effect on hip fracture in high-risk Japanese female osteoporosis patients for fracture with a history of unilateral hip fracture.
Appendix
Available only for authorised users
Literature
1.
Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000 March 27–29; 17: 1–45
2.
Kanis JA, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRef
3.
Looker AC, Melton LJ, Harris TB et al (2009) Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 25(1):64–7CrossRef
4.
Guidelines for prevention and treatment of osteoporosis. (2006) ed. Life Science Publishing Co., Ltd
5.
Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef
6.
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMedCrossRef
7.
Orimo H, Yaegashi Y, Onoda T (2009) Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 4:71–77PubMedCrossRef
8.
Prevention and management of osteoporosis. Report of a WHO scientific group. WHO Technical Report Series 921, 2003
9.
Geusens P, McClung M (2001) Review of risedronate in the treatment of osteoporosis. Expert Opin Pharmacother 2:2011–2025PubMedCrossRef
10.
Fogelman I, Ribot C, Smith R et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895–1900PubMedCrossRef
11.
Fukunaga M, Kushida K, Kishimoto H et al (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971–979PubMedCrossRef
12.
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) study group. JAMA 282(14):1344–1352PubMedCrossRef
13.
Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83–91PubMedCrossRef
14.
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef
15.
Masud T, McClung M, Geusens P (2009) Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 4:445–449PubMedCrossRef
16.
MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213PubMed
17.
Yoshihiro S, Tomohiro K, Kei S et al (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease. Arch Inter Med 165:1737–1742CrossRef
18.
Yoshihiro S, Jun I, Tomohiro K et al (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Inter Med 165:1743–1748CrossRef
19.
Investigational Committee for Osteoporosis Diagnosis Standard, Japanese Society for Bone and Mineral Research (2001) Diagnosis standard for primary osteoporosis (2000 revised edition). J Jpn Soc Bone Miner Res 8:76–82
20.
De Laet C, Kanis JA, Odén A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338PubMedCrossRef
21.
Chevalley T, Guilley E, Herrmann FR et al (2007) Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40:1284–1289PubMedCrossRef
22.
Melton LJ 3rd, Kearns AE, Atkinson EJ (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694PubMedCrossRef
23.
Hagino H, Furukawa K, Fujiwara S et al (2009) Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int 20:543–548PubMedCrossRef
24.
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef
25.
Peter CP, Kindt MV, Majka JA (1998) Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009–1015PubMedCrossRef
26.
Kushida K, Kishimoto H et al (2002) Efficacy and safety of long-term treatment with risedronate in patients with osteoporosis and osteopenia. Osteoporos Jpn 10:85–97, in Japanese
27.
Hooven FH, Adachi JD, Adami S et al (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 20:1107–1116PubMedCrossRef
Metadata
Title
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
Authors
M. Osaki
K. Tatsuki
T. Hashikawa
T. Norimatsu
K. Chiba
S. Motokawa
I. Furuichi
Y. Doiguchi
K. Aoyagi
H. Shindo
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 2/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1556-7

Other articles of this Issue 2/2012

Osteoporosis International 2/2012 Go to the issue

Original Article

Algorithms can be used to identify fragility fracture cases in physician-claims databases

Original Article

Site-specific differences in bone mineral density in black and white premenopausal South African women

Original Article

Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study

Original Article

Osteoporotic changes of subchondral trabecular bone in osteoarthritis of the knee: a 3-T MRI study

Review

Epidemiology and structural basis of racial differences in fragility fractures in Chinese and Caucasians

Original Article

A study of relationships between bone-related vitamins and minerals, related risk markers, and subsequent mortality in older British people: the National Diet and Nutrition Survey of People Aged 65 Years and Over